Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
Authors:
- Waka Yokoyama-KokuryoWYWaka Yokoyama-Kokuryo
- Hayato YamazakiHYHayato Yamazaki
- Tsutomu TakeuchiTTTsutomu Takeuchi
- Koichi AmanoKAKoichi Amano
- Jun KikuchiJKJun Kikuchi
- Tsuneo KondoTKTsuneo Kondo
- Seiji NakamuraSNSeiji Nakamura
- Ryoko SakaiRSRyoko Sakai
- Fumio HiranoFHFumio Hirano
- Toshihiro NankiToshihiro Nanki
- Ryuji KoikeRKRyuji Koike
- Masayoshi HarigaiMHMasayoshi Harigai
Open Access
- 12 March 2020
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 22 (1) , 1-8
Abstract
Background: Abatacept (ABA) is a biological disease-modifying antirheumatic drug (bDMARD) for rheumatoid arthritis (RA). The aim of this study was to identify molecules that are associated with therapeutic responses to ABA in patients with RA. Methods: Peripheral blood was collected using a PAX gene Blood RNA kit from 45 bDMARD-naïve patients with RA at baseline and at 6 months after the initiation of ABA treatment. Gene expression levels of responders (n = 27) and non-responders (n = 8) to ABA treatment among patients with RA at baseline were compared using a microarray. The gene expression levels were confirmed using real-time quantitative polymerase chain reaction (RT-qPCR). Results: Gene expression analysis revealed that the expression levels of 218 genes were significantly higher and those of 392 genes were significantly lower in the responders compared to the non-responders. Gene ontology analysis of the 218 genes identified “response to type I interferon (IFN)” with 24 type I IFN-related genes. RT-qPCR confirmed that there was a strong correlation between the score calculated using the 24 genes and that using OAS3, MX1, and IFIT3 (type I IFN score) (rho with the type I IFN score 0.981); the type I IFN score was significantly decreased after treatment with ABA in the responders (p < 0.05), but not in the non-responders. The receiver operating characteristic curve analysis of the type I IFN score showed that sensitivity, specificity, and AUC (95% confidence interval) for the responders were 0.82, 1.00, and 0.92 (0.82–1.00), respectively. Further, RT-qPCR demonstrated higher expression levels of BATF2, LAMP3, CD83, CLEC4A, IDO1, IRF7, STAT1, STAT2, and TNFSF10 in the responders, all of which are dendritic cell-related genes or type I IFN-related genes with significant biological implications. Conclusion: Type I IFN score and expression levels of the nine genes may serve as novel biomarkers associated with a clinical response to ABA in patients with RA.Keywords
Funding Information
- Tokyo Women's Medical University
- Ministry of Health, Labour and Welfare (#15K19570, H30-meneki-shitei-002)
This publication has 42 references indexed in Scilit:
- The type I IFN signature as a biomarker of preclinical rheumatoid arthritisAnnals of the Rheumatic Diseases, 2013
- Compensatory dendritic cell development mediated by BATF–IRF interactionsNature, 2012
- The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patientsArthritis Research & Therapy, 2012
- Importance of Correlation between Gene Expression Levels: Application to the Type I Interferon Signature in Rheumatoid ArthritisPLOS ONE, 2011
- Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatmentArthritis Research & Therapy, 2010
- Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritisRheumatology, 2009
- Rheumatoid Arthritis Synovium Contains Two Subsets of CD83−DC-LAMP− Dendritic Cells with Distinct Cytokine ProfilesThe American Journal of Pathology, 2008
- Adjusting batch effects in microarray expression data using empirical Bayes methodsBiostatistics, 2006
- TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITYAnnual Review of Immunology, 2005
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996